CureVac N.V. is a clinical-stage biopharmaceutical company that focuses on developing transformative mRNA-based medicines, including vaccines for SARS-CoV-2, influenza, rabies virus, yellow fever, and malaria, among others. It is also working on RNA-based cancer immunotherapies for the treatment of melanoma, adenoidcystic carcinoma, and squamous cell cancer of the skin, head, and neck. Founded in 2000 and headquartered in Germany, the company is advancing its pipeline through various clinical trials.